Disclosure Intervention for People in Treatment for Opioid Use Disorder
Part of paid clinical trials in Wilmington, Delaware.
- Sponsor
- University of Delaware
- Study ID
- NCT06458985
- Status
- Recruiting
Conditions
- Opioid Use Disorder
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Disclosing Recovery: A Decision Aid and Toolkit — BEHAVIORALThe Disclosing Recovery intervention is designed to help people in treatment for opioid use disorder (1) make key decisions regarding disclosure, including whether, why, what, how, and when to disclose, and (2) build skills to disclose, including planning what to say, practicing disclosure, and preparing for negative responses.
Study Details
The goal of this clinical trial is to test a disclosure intervention among people in treatment for opioid use disorder. The main question it aims to answer is whether people who receive a disclosure intervention have better treatment- and recovery-related outcomes one year after receiving the intervention. Participants will complete a brief disclosure intervention designed to help them (1) make key disclosures related to disclosure and (2) build skills to disclose. Researchers will compare results to participants in a waitlist comparator condition, who receive the intervention at the end of the study.
Key Dates
- Start date
- May 20, 2024
- Status verified
- Jul 2025
- Primary completion
- May 1, 2028
- Completion
- Aug 31, 2028
Study Design
- Enrollment
- 480 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Disclosing RecoveryParticipants complete a one-hour disclosure intervention for people in treatment for opioid use disorder. The intervention is facilitated by a workbook and accompanying worksheet.
- No Intervention: Waitlist ComparatorParticipants do not complete the disclosure intervention at their baseline appointment. They are given the opportunity to complete the disclosure intervention at their final appointment.
Primary Outcome Measure
Retention in treatment [ Time Frame: 1 year ]
Central Contacts
- Valerie A Earnshaw, PhD1-302-831-4772
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Brandywine Counseling & Community Services | Wilmington | Delaware | 19805 |
Find similar trials in Wilmington, DE
By research site
Related Studies
- A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use DisorderPHASE4 · Recruiting · VA Office of Research and Development · Tuscaloosa, Alabama
- Houston Emergency Opioid Engagement SystemPHASE4 · Enrolling By Invitation · The University of Texas Health Science Center, Houston · Houston, Texas
- Adjunctive Effects of Psilocybin and a Formulation of BuprenorphinePHASE1 · Recruiting · University of Wisconsin, Madison · Madison, Wisconsin
- Effects of Pharmacological Stress and rTMS on Executive Function in Opioid Use DisorderPHASE2 · Not Yet Recruiting · Wayne State University · Detroit, Michigan